

TREMFYA (Guselkumab) PRESCRIBER ORDER FORM						
FAX COMPLETED FORM, INSURANCE INFORMATION, CLINICAL DOCUMENTATION (LATEST NOTES & LABS) to: (757) 466-1128						
□ NEW PATIENT OR						
	ORDER:	Drug Change	Dose Change	Interval Change		
Patient Nar	me:		Phone:		Date of Birth:	
Address:						
Allergies:						
Height: 🗆 inches 🗆 cm Weight: 🗆 lbs 🗆 kg						
CLINICAL INFORMATION						
Primary Dia	agnosis Descri	ption:		ONMATION	ICD-10 Code:	
Is this the f	first dose?	□ Yes			1	
No – date of next dose due:						
Treatments – Tried and Failed:						
	PPD (negat	ive) – date:		Hepatitis Status	· ·	
				•	□ Complete HepBsAg and anti-HBc, anti-HBs antibodies	
□ Quantiferon or T Spot Assay result / date: □ Complete Anti-HCV a						
□ Past positive TB infection, course taken:						
□ Active TB						
TREMFYA (Guselkumab) PRESCRIPTION						
TREMFYA refill as directed x 1 year.						
Induction Dose: <a>D Infuse 200mg IV over at least 1 hour Weeks 0, 4, and 8.</a>						
Maintenance Dose: 🛛 Inject 100mg every 8 weeks starting week 16.						
OR						
Inject 200mg SC every 4 weeks if needed for symptom control starting week 12.						
_			ANCILLAR	Y ORDERS		
Pre - Medication Orders						
Acetaminophen 650mg PO 30 minutes before infusion.						
Diphenhydramine 25mg PO 30 minutes before infusion.						
Methylprednisolone Succinate 125mg IV push 20 minutes before infusion.						
Other:						
PRN Hypersensitivity Meds:						
Epinephrine 0.3mg						
<ul> <li>Solu-Cortef 100mg</li> </ul>						
Solu-Medrol 125mg						
<ul> <li>Diphenhydramine 25-50mg</li> </ul>						
<ul> <li>NS 500 ML (&gt;30kg)</li> </ul>						
I certify that the use of the indicated treatment is medically necessary, and I will be supervising the patient's treatment.						
Prescriber Signature: Date:						
			PRESCRIBER I			
Prescriber	Name:		Phone:		Fax:	
Address:					NPI:	
City, State:			Zip:		Office Contact:	
CONFIDENTIAL HEALTI	H INFORMATION: Healthcare		related to a person's healthcare. It is being		r under circumstances that do not require authorization. You are obligated to	
maintain it in a safe, secure, and confidential manner. Re-disclosure of this information is prohibited unless permitted by law or appropriate customer/patient authorization is obtained. Unauthorized re-disclosure of failure to maintain confidentiality could subject you to penalties described in federal and state laws. IMPORTANT WARNING: This message is intended for the use of the person or entity to who it is addressed and may contain information that is privileged and confidential, the disclosure of which is governed by applicable law. If the reader of this message is not the intended recipient, or agent responsible for delivering it to the intended recipient, you are hereby notified that any dissemination, distribution or copying of the information is STRICTLY PROHIBITED. If you have received this message in error, please notify us immediately. Brand names are the property of their respective owners.						